NEW YORK (GenomeWeb) – Roche said today that its diagnostics division revenues grew 6 percent in the first nine months of 2018, driven mainly by growing demand for its immunodiagnostics solutions.
For the nine months ended Sept. 30, the Basel, Switzerland-based pharmaceuticals and diagnostics giant's total revenues rose 7 percent to CHF 42.08 billion ($42.42 billion) from CHF 39.43 billion during the same period in 2017.